2.2999

4.07% +0.0899

After Hours: 2.2999

Anebulo Pharmaceuticals Inc (ANEB)

Overview News Price History Financials Discussions Forecast

Anebulo Pharmaceuticals Inc stock is currently priced at $2.2999, with a 24-hour trading volume of 7,256. It has seen a +4.07% increased in the last 24 hours and a -23.33% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $2.28 pivot point. If it approaches the $2.37 resistance level, significant changes may occur.

Previous Close:

$2.21

Open:

$2.21

24h Volume:

7,256

Market Cap:

$59.64M

Revenue:

Net Income/Loss:

$-10.49M

P/E Ratio:

-4.8934

EPS:

-0.47

Net Cash Flow:

$-9.58M

1W Performance:

-23.59%

1M Performance:

-23.33%

6M Performance:

+6.48%

1Y Performance:

-0.87%

1D Range:

$2.05

$2.2999

52W Range:

$1.62

$4.05

Anebulo Pharmaceuticals Inc Stock (ANEB) Company Profile

Name

Anebulo Pharmaceuticals Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

512-598-0931

Address

1415 Ranch Road 620 South, Suite 201, Lakeway

Employee

Twitter

Next Earnings Date

2024-05-09

Latest SEC Filings

ANEB's Discussions on Twitter

Anebulo Pharmaceuticals Inc Stock (ANEB) Latest News

Burnham (OTCMKTS:BURCA) Shares Cross Above 200 Day Moving Average of $12.38 - Defense World

Defense World

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Down 10.9% in April - Defense World

Defense World

Nitto Denko (OTCMKTS:NDEKY) Stock Passes Below Fifty Day Moving Average of $44.80 - Defense World

Defense World

Bowleven (LON:BLVN) Stock Price Up 14.3% - Defense World

Defense World

Drum Income Plus REIT (LON:DRIP) Stock Price Passes Below Fifty Day Moving Average of $50.00 - Defense World

Defense World

Metal Tiger (LON:MTR) Shares Pass Above 50 Day Moving Average of $9.06 - Defense World

Defense World

Anebulo Pharmaceuticals Inc Stock (ANEB) Financials Data

Anebulo Pharmaceuticals Inc (ANEB) Net Income 2024

ANEB net income (TTM) was -$10.49 million for the quarter ending December 31, 2023, a +1.38% increase year-over-year.

Anebulo Pharmaceuticals Inc (ANEB) Cash Flow 2024

ANEB recorded a free cash flow (TTM) of -$9.58 million for the quarter ending December 31, 2023, a -18.22% decrease year-over-year.

Anebulo Pharmaceuticals Inc (ANEB) Earnings per Share 2024

ANEB earnings per share (TTM) was -$0.42 for the quarter ending December 31, 2023, a +4.55% growth year-over-year.

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. The company was incorporated in 2020 and is based in Lakeway, Texas.